Literature DB >> 17885242

A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis.

M A Rocca1, T Mondria, P Valsasina, M P Sormani, Z H Flach, P A Te Boekhorst, G Comi, R Q Hintzen, M Filippi.   

Abstract

BACKGROUND AND
PURPOSE: In multiple sclerosis (MS), autologous hematopoietic stem cell transplantation (AHSCT) induces a profound suppression of clinical activity and MR imaging-detectable inflammation, but it may be associated with a rapid brain volume loss in the months subsequent to treatment. The aim of this study was to assess how AHSCT affects medium-term evolution of brain atrophy in MS.
MATERIALS AND METHODS: MR imaging scans of the brain from 14 patients with rapidly evolving secondary-progressive MS obtained 3 months before and every year after AHSCT for 3 years were analyzed. Baseline normalized brain volumes and longitudinal percentage of brain volume changes (PBVCs) were assessed using the Structural Image Evaluation of Normalized Atrophy software.
RESULTS: The median decrease of brain volume was 1.92% over the first year after AHSCT and then declined to 1.35% at the second year and to 0.69% at the third year. The number of enhancing lesions seen on the pretreatment scans was significantly correlated with the PBVCs between baseline and month 12 (r = -0.62; P = .02); no correlation was found with the PBVCs measured over the second and third years.
CONCLUSIONS: After AHSCT, the rate of brain tissue loss in patients with MS declines dramatically after the first 2 years. The initial rapid development of brain atrophy may be a late consequence of the pretransplant disease activity and/or a transient result of the intense immunoablative conditioning procedure.

Entities:  

Mesh:

Year:  2007        PMID: 17885242      PMCID: PMC8134216          DOI: 10.3174/ajnr.A0644

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  16 in total

1.  Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS.

Authors:  A Saiz; Y Blanco; E Carreras; J Berenguer; M Rovira; T Pujol; P Marín; T Arbizu; F Graus
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

Review 2.  Autologous haematopoietic-stem-cell transplantation for multiple sclerosis.

Authors:  Yolanda Blanco; Albert Saiz; Enric Carreras; Francesc Graus
Journal:  Lancet Neurol       Date:  2005-01       Impact factor: 44.182

Review 3.  Hematopoietic stem cell transplantation for multiple sclerosis.

Authors:  Richard K Burt; Bruce Cohen; John Rose; Finn Petersen; Yu Oyama; Dusan Stefoski; George Katsamakis; Ewa Carrier; Tomas Kozak; Paolo A Muraro; Roland Martin; Roger Hintzen; Shimon Slavin; Dimitrios Karussis; Shalom Haggiag; Julio C Voltarelli; George W Ellison; Borko Jovanovic; Uday Popat; Joseph McGuirk; Laisvyde Statkute; Larissa Verda; Judith Haas; Renate Arnold
Journal:  Arch Neurol       Date:  2005-06

Review 4.  Magnetic resonance spectroscopy in the monitoring of multiple sclerosis.

Authors:  Ponnada A Narayana
Journal:  J Neuroimaging       Date:  2005       Impact factor: 2.486

5.  Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis.

Authors:  J T Chen; D L Collins; H L Atkins; M S Freedman; A Galal; D L Arnold
Journal:  Neurology       Date:  2006-06-27       Impact factor: 9.910

6.  Neurobehavioral toxicity of total body irradiation: a follow-up in long-term survivors.

Authors:  M Peper; S Steinvorth; P Schraube; S Fruehauf; R Haas; B N Kimmig; F Lohr; F Wenz; M Wannenmacher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-15       Impact factor: 7.038

7.  Axonal transection in the lesions of multiple sclerosis.

Authors:  B D Trapp; J Peterson; R M Ransohoff; R Rudick; S Mörk; L Bö
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

Review 8.  The relation between MRI measures of inflammation and neurodegeneration in multiple sclerosis.

Authors:  Matilde Inglese; Beatrice Benedetti; Massimo Filippi
Journal:  J Neurol Sci       Date:  2005-04-22       Impact factor: 3.181

9.  Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation.

Authors:  M Inglese; G L Mancardi; E Pagani; M A Rocca; A Murialdo; R Saccardi; G Comi; M Filippi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-04       Impact factor: 10.154

Review 10.  Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.

Authors:  David H Miller; Frederik Barkhof; Joseph A Frank; Geoffrey J M Parker; Alan J Thompson
Journal:  Brain       Date:  2002-08       Impact factor: 13.501

View more
  9 in total

1.  [Stem cell transplantation for multiple sclerosis. Hamburg experiences and state of international research].

Authors:  J-P Stellmann; K H Stürner; F Ufer; S Havemeister; J Pöttgen; F Ayuk Ayuketang; N Kröger; M A Friese; C Heesen
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 2.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

Review 3.  Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience.

Authors:  Daniela Currò; Gianluigi Mancardi
Journal:  Neurol Sci       Date:  2016-04-12       Impact factor: 3.307

Review 4.  Cell Therapy for Multiple Sclerosis.

Authors:  Pamela Sarkar; Claire M Rice; Neil J Scolding
Journal:  CNS Drugs       Date:  2017-06       Impact factor: 6.497

Review 5.  Feasibility of cell therapy in multiple sclerosis: a systematic review of 83 studies.

Authors:  Abdolreza Ardeshiry Lajimi; Majid Farshdousti Hagh; Najmaldin Saki; Esmaeil Mortaz; Masoud Soleimani; Fakher Rahim
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2013

6.  Methemoglobin is an endogenous toll-like receptor 4 ligand-relevance to subarachnoid hemorrhage.

Authors:  Min Seong Kwon; Seung Kyoon Woo; David B Kurland; Sung Hwan Yoon; Andre F Palmer; Uddyalok Banerjee; Sana Iqbal; Svetlana Ivanova; Volodymyr Gerzanich; J Marc Simard
Journal:  Int J Mol Sci       Date:  2015-03-05       Impact factor: 5.923

Review 7.  Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis.

Authors:  Madeline Bross; Melody Hackett; Evanthia Bernitsas
Journal:  Int J Mol Sci       Date:  2020-06-17       Impact factor: 5.923

Review 8.  Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature.

Authors:  Francesco Patti; Clara Grazia Chisari; Simona Toscano; Sebastiano Arena; Chiara Finocchiaro; Vincenzo Cimino; Giuseppe Milone
Journal:  J Clin Med       Date:  2022-02-11       Impact factor: 4.241

9.  The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.

Authors:  A G Willison; T Ruck; G Lenz; H P Hartung; S G Meuth
Journal:  J Neurol       Date:  2022-04-11       Impact factor: 4.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.